Fixed dosing of liposomal amphotericin b in morbidly obese individuals

Roeland E. Wasmann; Cornelis Smit; Eric P.H. van Dongen; René M.J. Wiezer; Jill Adler-Moore; Yvo M. de Beer; David M. Burger; Catherijne A.J. Knibbe; Roger J.M. Brüggemann

doi:10.1093/cid/ciz885

Fixed dosing of liposomal amphotericin b in morbidly obese individuals

Roeland E. Wasmann
, Cornelis Smit
, Eric P.H. van Dongen
, René M.J. Wiezer
, Jill Adler-Moore
, Yvo M. de Beer
, David M. Burger
, Catherijne A.J. Knibbe
, Roger J.M. Brüggemann

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively).

Original language	English
Pages (from-to)	2213-2215
Number of pages	3
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	70
Issue number	10
DOIs	https://doi.org/10.1093/cid/ciz885
Publication status	Published - 6 May 2020
Externally published	Yes

Keywords

Fungal infection
Fungal treatment
Obese
Optimal dosing
Population pharmacokinetics

Access to Document

10.1093/cid/ciz885

Cite this

Wasmann, R. E., Smit, C., van Dongen, E. P. H., Wiezer, R. M. J., Adler-Moore, J., de Beer, Y. M., Burger, D. M., Knibbe, C. A. J., & Brüggemann, R. J. M. (2020). Fixed dosing of liposomal amphotericin b in morbidly obese individuals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 70(10), 2213-2215. https://doi.org/10.1093/cid/ciz885

@article{44da53a58f3547cfa3f886e6887f68b8,

title = "Fixed dosing of liposomal amphotericin b in morbidly obese individuals",

abstract = "In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively).",

keywords = "Fungal infection, Fungal treatment, Obese, Optimal dosing, Population pharmacokinetics",

author = "Wasmann, \{Roeland E.\} and Cornelis Smit and \{van Dongen\}, \{Eric P.H.\} and Wiezer, \{Ren{\'e} M.J.\} and Jill Adler-Moore and \{de Beer\}, \{Yvo M.\} and Burger, \{David M.\} and Knibbe, \{Catherijne A.J.\} and Br{\"u}ggemann, \{Roger J.M.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [email protected]",

year = "2020",

month = may,

day = "6",

doi = "10.1093/cid/ciz885",

language = "English",

volume = "70",

pages = "2213--2215",

journal = "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",

issn = "1537-6591",

publisher = "Oxford University Press",

number = "10",

}

Wasmann, RE, Smit, C, van Dongen, EPH, Wiezer, RMJ, Adler-Moore, J, de Beer, YM, Burger, DM, Knibbe, CAJ & Brüggemann, RJM 2020, 'Fixed dosing of liposomal amphotericin b in morbidly obese individuals', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 70, no. 10, pp. 2213-2215. https://doi.org/10.1093/cid/ciz885

TY - JOUR

T1 - Fixed dosing of liposomal amphotericin b in morbidly obese individuals

AU - Wasmann, Roeland E.

AU - Smit, Cornelis

AU - van Dongen, Eric P.H.

AU - Wiezer, René M.J.

AU - Adler-Moore, Jill

AU - de Beer, Yvo M.

AU - Burger, David M.

AU - Knibbe, Catherijne A.J.

AU - Brüggemann, Roger J.M.

N1 - Publisher Copyright: © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [email protected]

PY - 2020/5/6

Y1 - 2020/5/6

N2 - In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively).

AB - In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively).

KW - Fungal infection

KW - Fungal treatment

KW - Obese

KW - Optimal dosing

KW - Population pharmacokinetics

UR - https://www.scopus.com/pages/publications/85078339899

U2 - 10.1093/cid/ciz885

DO - 10.1093/cid/ciz885

M3 - Article

C2 - 31588493

AN - SCOPUS:85078339899

SN - 1537-6591

VL - 70

SP - 2213

EP - 2215

JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

IS - 10

ER -

Fixed dosing of liposomal amphotericin b in morbidly obese individuals

Abstract

Keywords

Access to Document

Fingerprint

Cite this